Amgen Inc. $AMGN Shares Sold by Argent Trust Co

Argent Trust Co cut its position in shares of Amgen Inc. (NASDAQ:AMGN) by 29.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 21,826 shares of the medical research company’s stock after selling 9,070 shares during the quarter. Argent Trust Co’s holdings in Amgen were worth $6,159,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Brighton Jones LLC boosted its position in shares of Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after buying an additional 5,226 shares during the period. Sivia Capital Partners LLC lifted its position in Amgen by 10.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after acquiring an additional 114 shares in the last quarter. Schnieders Capital Management LLC. boosted its holdings in Amgen by 29.3% in the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after acquiring an additional 5,853 shares during the period. Oppenheimer Asset Management Inc. grew its position in Amgen by 23.9% in the second quarter. Oppenheimer Asset Management Inc. now owns 1,098 shares of the medical research company’s stock valued at $307,000 after acquiring an additional 212 shares in the last quarter. Finally, Assetmark Inc. raised its stake in shares of Amgen by 15.3% during the second quarter. Assetmark Inc. now owns 202,907 shares of the medical research company’s stock valued at $56,654,000 after purchasing an additional 26,939 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently issued reports on AMGN. TD Cowen reaffirmed a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Oppenheimer set a $400.00 target price on Amgen and gave the company an “outperform” rating in a research note on Thursday, January 29th. Piper Sandler boosted their price target on Amgen from $381.00 to $432.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. The Goldman Sachs Group increased their price target on Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a report on Wednesday, February 4th. Finally, Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Amgen currently has an average rating of “Moderate Buy” and a consensus target price of $351.76.

Amgen Stock Up 2.3%

Shares of Amgen stock opened at $388.16 on Friday. The company has a market capitalization of $209.25 billion, a P/E ratio of 27.28, a PEG ratio of 3.76 and a beta of 0.46. The business’s fifty day moving average price is $348.89 and its two-hundred day moving average price is $319.48. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $390.14. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. During the same period last year, the firm earned $5.31 EPS. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be issued a dividend of $2.52 per share. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio is 70.84%.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported a new evolocumab bioavailability study that refines dosing/PK assessment for its PCSK9 cholesterol franchise, signaling management’s continued investment in a long‑lived cardiovascular product line and potential lifecycle optimization. Amgen Fine-Tunes Evolocumab
• Positive Sentiment: Amgen advanced maridebart (cafraglutide) toward a Phase 2b obesity and liver‑fat trial — news that expands the company’s obesity pipeline and supports upside potential beyond core biologics. Pipeline progress tends to lift pharma multiples. Amgen Advances Maridebart
• Positive Sentiment: Coverage and momentum narratives are supportive — Zacks highlights AMGN as a top long‑term momentum stock, which can attract trend‑driven and fund flows. Why Amgen is a Top Momentum Stock
• Positive Sentiment: Market headlines note AMGN reaching an all‑time high and outperforming the Dow recently — reinforcement for bullish sentiment and potential technical buying. Amgen stock hits all-time high Is Amgen Stock Outperforming the Dow?
• Neutral Sentiment: Biotech sector activity: a large biotech IPO (Generate Biomedicines) indicates healthy capital markets for life sciences, which can be a neutral tailwind for large biotech names but doesn’t directly change Amgen’s fundamentals. Generate caps a strong month for biotech IPOs
• Neutral Sentiment: Minor portfolio rebalancing: a small sale by Bradley Foster & Sargent reduced a modest position in AMGN — not material to shares outstanding or sentiment. Bradley Foster & Sargent sells AMGN
• Negative Sentiment: Policy risk: a proposed U.S. bill to tighten rules on corporate inversions mentions AMGN among companies potentially affected by changes to international tax treatment — could raise longer‑term tax/structural uncertainty if enacted. Impact is uncertain and likely small near term. Stop Corporate Inversions Act of 2026
• Neutral Sentiment: Reported short‑interest data in feeds looks inconsistent (zeros/NaN) and should be treated with caution; no clear signal from short interest trends. (data sources above).

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.